Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
1992-7-1
|
pubmed:abstractText |
African Green monkeys were injected (2 x daily subcutaneously for six months) with human GRF(1-44)-NH2 (10 micrograms/kg BW) or a more potent analog, [desNH2Tyr1,Ala15]-hGRF(1-29)-NH2 (2 micrograms/kg BW) to determine the potential of each peptide to induce antibody formation. Blood samples were taken every two weeks, diluted 1:100 and tested for ability to bind radioiodinated hGRF. One animal in the hGRF(1-44)-NH2 group [N = 6] produced low-titer GRF antibodies by 6 weeks (19% binding) and continued throughout the 24 weeks of treatment (average = 50-60% binding). Similarly, one animal in the hGRF analog group [N = 6] displayed low-titer GRF antibodies by 18 weeks (14% binding), with the highest binding observed at 24 weeks (51% binding). Subsequent dilutions (1:1,000 and 1:3,000) of these bleedings confirmed that higher GRF antibody titers were not masked by antibody excess. Dialyzed sera from these two animals did not affect the abilities of hGRF(1-44)-NH2 or [desNH2Tyr1,Ala15]-hGRF(1-29)-NH2 to stimulate GH secretion by rat pituitary cells in vitro. After 20 weeks of treatment, significant GH responses (increased mean GH area under the curve 2.3-2.5 fold and GH peak 3.5-3.7 fold, that of control) were observed following hGRF or hGRF analog injection. Therefore, the low titer GRF antibodies detected in monkey sera during six months of treatment with hGRF or a potent analog were biologically non-neutralizing.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Growth Hormone-Releasing Hormone,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Sermorelin,
http://linkedlifedata.com/resource/pubmed/chemical/somatotropin releasing hormone...
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0018-5043
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
23
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
530-4
|
pubmed:dateRevised |
2009-2-19
|
pubmed:meshHeading |
pubmed-meshheading:1816063-Animals,
pubmed-meshheading:1816063-Antibodies,
pubmed-meshheading:1816063-Antibody Formation,
pubmed-meshheading:1816063-Cells, Cultured,
pubmed-meshheading:1816063-Cercopithecus aethiops,
pubmed-meshheading:1816063-Growth Hormone-Releasing Hormone,
pubmed-meshheading:1816063-Injections, Subcutaneous,
pubmed-meshheading:1816063-Peptide Fragments,
pubmed-meshheading:1816063-Pituitary Gland,
pubmed-meshheading:1816063-Radioimmunoassay,
pubmed-meshheading:1816063-Sermorelin
|
pubmed:year |
1991
|
pubmed:articleTitle |
Effect of human growth hormone-releasing factor and a potent analog on antibody formation in African green monkeys.
|
pubmed:affiliation |
Department of Animal Science, Hoffmann-La Roche, Inc., Nutley, New Jersey.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|